Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) recently cut its 2026 GAAP earnings guidance and reported a quarterly net loss, despite a strong rebound in share price momentum. The article explores two contrasting valuation narratives: one suggesting the stock is 14.7% undervalued based on primate supply constraints, and another from the SWS DCF model indicating it is significantly overvalued. Investors are encouraged to analyze the data and risks themselves due to the split sentiment.